Noxxon Pharma has secured a positive recommendation from the Data Safety Monitoring Board (DSMB) to continue recruiting patients for the NOX-A12 plus radiotherapy brain cancer study.

The independent body concluded that it is safe to continue with the enrolment after assessing safety data from the initial four weeks of treatment of the first patient recruited in the third and final dose cohort of the study.

The Phase I/II clinical study involves testing three dose regimens of NOX-A12 (200mg, 400mg and 600mg/week) along with external-beam radiotherapy in newly diagnosed brain cancer patients.

The participating clinical centres have now started final patient recruitment for the last and highest dose group. Once all patients in the third cohort have received four weeks of treatment, DSMB will again assess safety and tolerability.

The meeting will subsequently determine the recommended dose for the next randomised, controlled brain cancer trial.

Noxxon CEO Aram Mangasarian said: “We are pleased by the safety data confirmation of the DSMB, as it will allow our study to progress and the last patients to receive treatment at the highest planned dose of NOX-A12.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This achievement brings us one step closer to a topline data readout for this cohort sometime around the end of Q3 2021. As the study advances, we will be analysing data which will be used to define the recommended dose and guide preparations for a potentially registrational Phase II study.

“The recent capital raise plus available financing vehicles secure Noxxon’s financial runway well into 2022, thereby allowing us to address operational matters crucial for the future of the company.”